Investor Presentaiton
Strong business momentum
Diversified portfolio growth
Efficient compounding engine
Sustainable long-term growth
...expected to power growth through 2030 and beyond
2030e sales ($ in billions)(2)
Illustrative 2030e Adjusted Cash Receipts (1) ("top-line")
Therapy
Risk adj.
Potential '30
Non-risk adj. blockbuster
Royalty rate (%)
Omecamtiv
$0.5
$1.8
Mid-single digits
Incl. gantenerumab
Zavegepant
$1.1
$1.5
Low-single digits
PT027
$1.0
$1.8
Low-single digits
Otilimab
$0.5
$1.2
Double digits (3)
Seltorexant
$0.4
$0.5
Mid-single digits
Aficamten
$1.9
$4.2
Mid-single digits
Incl. gantenerumab
BCX9930
$0.3
$0.6
Mid-single digits
Pelabresib
$0.4
$0.6
3%
$400-800m
CPI-0209
$0.0
$0.2
3%
Total
~$6.0
~$12.0
~Mid-single digits
$200-400m
Gantenerumab
$3.6
$8.1
3.3-4.2% (3)
excl. gantenerumab
(incl. brain shuttle)
Risk adjusted (2030e)
excl. gantenerumab
Non-risk adjusted (2030e)
ROYALTY PHARMA
1. See slide 114 for definitions and factors that may impact the achievement of our growth outlook.
2. Consensus sales estimates from Visible Alpha as of May 9, 2022; manual broker consensus sales for therapies without available Visible Alpha estimates.
3. Royalty Pharma is entitled to 80% of tiered double-digit royalties for otilimab and 60% of tiered 5.5% to 7.0% royalties for gantenerumab.
93View entire presentation